Predictions
Seelos Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.15
24.11.23
24.11.23
-
24.11.26
24.11.26
-34.71%
22.08.24
22.08.24
Bio-Gate AG
Start price
Target price
Perf. (%)
€0.80
11.11.23
11.11.23
-
11.11.24
11.11.24
-
11.11.23
11.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Fuji Pharma Co. Ltd.
Start price
Target price
Perf. (%)
€8.90
11.11.23
11.11.23
€4.00
11.11.24
11.11.24
2.25%
25.11.23
25.11.23
PDS Biotechnology Corp.
Start price
Target price
Perf. (%)
€4.91
11.11.23
11.11.23
€2.00
11.11.24
11.11.24
12.13%
25.11.23
25.11.23
Fulgent Genetics Inc
Start price
Target price
Perf. (%)
€24.75
06.11.23
06.11.23
€29.00
27.02.24
27.02.24
-5.66%
18.02.24
18.02.24
Bio-Gate AG
Start price
Target price
Perf. (%)
€0.81
05.11.23
05.11.23
-
05.11.24
05.11.24
15.43%
11.11.23
11.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Eledon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€1.47
30.10.23
30.10.23
-
30.10.24
30.10.24
-27.89%
10.11.23
10.11.23
Eledon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.26
29.10.23
29.10.23
€2.80
30.09.25
30.09.25
-
30.10.23
30.10.23
Could be very worthwhile Investment >20% year
CEL-SCI Corp.
Start price
Target price
Perf. (%)
€1.51
23.10.23
23.10.23
-
23.10.24
23.10.24
-23.18%
28.10.23
28.10.23
Could be worthwhile Investment >10% per year
Inotiv Inc.
Start price
Target price
Perf. (%)
€2.32
16.10.23
16.10.23
-
16.10.24
16.10.24
34.48%
11.12.23
11.12.23
Probably not worthwhile Investment
Eledon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€1.28
01.10.23
01.10.23
€2.00
30.09.25
30.09.25
14.84%
29.10.23
29.10.23
Could be very worthwhile Investment >20% year
BioLine RX Ltd ADR
Start price
Target price
Perf. (%)
€1.64
30.09.23
30.09.23
€1.00
30.09.24
30.09.24
-9.76%
14.10.23
14.10.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation